| 摘要 |
The use of alpha -1L agonists is claimed for the treatment of urinary incontinence, esp. stress incontinence. Also claimed are (1) the use of alpha -1L agonists of formula (I) and their acid addn. salts (purpose not specified); 2) new phenylimino-imidazolidine cpds. of formula (II) (tautomers of pref. cpds. (I)); and 3) use of the new cpds. (II) as pharmaceuticals.Y = opt. substd. phenyl, opt. substd. naphthyl, or 5-6 membered (opt. up to max. unsatd.) heterocycle contg. O, S or N as heteroatom; X = NH, CH2, OCH2, OCH(CH3), -CH=N-NH, N=N or N(Z); Z = CH2CH-CH2 or cyclopropylmethyl; R1 = H, 1-6C alkyl, 3-6C cycloalkyl, 1-6C alkoxy, halo (pref. Cl or Br), CF3 or OCF3; R3,R5 = H, halo, 1-6C alkyl, 1-6C alkoxy, CF3 or OCF3; R4 = H, 1-6C alkyl or halo; R6, R7 = H, 3-6C cycloalkyl, 1-6C alkyl or 2-4C acyl, or NR6R7 = 5 or 6 membered opt. unsatd. ring (opt. contg. 1 or 2 further heteroatoms O,S and N, with the additional N opt. substd. by 1-4C alkyl, pref. Me); where 1-6C alkyl and alkoxy pref. have 1-4C and are esp. Me or OMe; and 3-6C cycloalkyl is pref. cyclopropyl. |
